Fig. 1: MRPL13 is an oncogene associated with OC progression and poor clinical prognosis. | Cell Death & Disease

Fig. 1: MRPL13 is an oncogene associated with OC progression and poor clinical prognosis.

From: MRPL13 enhances mitochondrial function and promotes tumor progression in ovarian cancer by inhibiting mPTP opening via SLC25A6

Fig. 1

A Relative MRPL13 mRNA expression in the GEPIA database. Box plots show MRPL13 mRNA expression in OC (n = 426) and the corresponding normal tissues (n = 88). Axis unit is log2(TPM + 1). B Relative MRPL13 mRNA expression in OC and normal tissues based on data from the GEO database (GSE26712, GSE54388, GSE18520, GSE27651 and GSE36668). C Relative MRPL13 protein expression in OC (n = 100) and normal tissues (n = 25) based on data from the UALCAN database. D Representative images of MRPL13 IHC staining in ovarian malignant tumors (n = 114), ovarian borderline tumors (n = 33), ovarian benign tumors (n = 31) and ovarian normal tissues (n = 13). Scale bar, 100 μm (×200, upper) and 50 μm (×400, lower). E Scatter plot of MRPL13 IHC staining scores in different ovarian tissues. F Kaplan–Meier analysis of the OS of patients with OC in the Shengjing hospital cohort based on MRPL13 expression evaluated in. G, H Kaplan–Meier analysis of the OS and PFS of patients with OC in Kaplan–Meier plotter database based on MRPL13 expression. I, J Forest plots of univariate and multivariate Cox regression analyses for various clinicopathological parameters in OC patients. *, P < 0.05; **, P < 0.01; ***, P < 0.001.

Back to article page